Compare SLDP & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SLDP | CTNM |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.2M | 550.7M |
| IPO Year | 2021 | 2024 |
| Metric | SLDP | CTNM |
|---|---|---|
| Price | $1.87 | $10.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.88 | ★ $21.43 |
| AVG Volume (30 Days) | ★ 3.1M | 692.4K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.56 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,747,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $1.80 | $6.73 |
| 52 Week High | $6.35 | $17.79 |
| Indicator | SLDP | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 51.26 |
| Support Level | N/A | $6.73 |
| Resistance Level | $2.49 | $13.72 |
| Average True Range (ATR) | 0.12 | 0.76 |
| MACD | -0.00 | 0.36 |
| Stochastic Oscillator | 7.38 | 77.30 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.